secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2022-09-21T23:59:59+00:00
Accession:  0001104659-22-101910
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec Pharma gets FDA approval for PEDMARK to reduce cisplatin-induced hearing loss in pediatric patients
--------------------------------------------------------------------------------

- FDA approved PEDMARK (sodium thiosulfate) for reducing ototoxicity in children aged 1 month+ with localized, non-metastatic solid tumors.
- PEDMARK is first and only FDA-approved therapy for this indication; based on two Phase 3 trials (SIOPEL6, COG ACCL0431).
- Hearing loss incidence: 21.4% vs 73.3% (COG ACCL0431, p=0.005) and 32.7% vs 63% (SIOPEL6, p=0.002) with PEDMARK plus cisplatin vs cisplatin alone.
- Common adverse reactions include vomiting, nausea, decreased hemoglobin, hypernatremia, hypokalemia; monitor electrolytes.
- PEDMARK also holds FDA Orphan Drug designation; EU MAA for PEDMARQSI is under EMA evaluation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465922101910/0001104659-22-101910-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465922101910/tm2226408d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-101910

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer